GlassScriptPhysician profile
Payman Sadeghi
NPI 1497895650
$4,774.90
in general payments reported to CMS, 2019-2025
26 companies · $982 in 2025
The $982 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $204 · 2021: $479 · 2022: $370 · 2023: $913 · 2024: $838 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,732.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,582.93 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $633.25 | 2023-2025 | |
| Lilly USA, LLC | $623.71 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $406.93 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $223.51 | 2019-2022 | |
| Impel Pharmaceuticals LLC | $204.67 | 2024-2025 | Trudhesa |
| Assertio Therapeutics, INC. | $133.00 | 2019-2020 | |
| Lundbeck LLC | $131.44 | 2021-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $107.40 | 2023-2024 | Ztlido |
| Supernus Pharmaceuticals, INC. | $80.72 | 2019-2020 | |
| Allergan, INC. | $72.17 | 2020 | |
| Axsome Therapeutics, INC. | $71.56 | 2025 | Symbravo |
| Zyla Life Sciences, INC. | $68.72 | 2019 | |
| Amneal Pharmaceuticals LLC | $56.76 | 2019-2025 | Brekiya |
| Impel Pharmaceuticals INC. | $52.75 | 2023 | Trudhesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $49.52 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $43.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.14 | 2022 | |
| Upsher-Smith Laboratories LLC | $35.89 | 2019 | |
| Azurity Pharmaceuticals, INC. | $30.06 | 2023-2024 | Horizant, Horizant |
| Currax Pharmaceuticals LLC | $26.52 | 2019-2020 | |
| Argenx US, INC. | $24.26 | 2024 | Vyvgart Hytrulo |
| Tersera Therapeutics LLC | $22.44 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.66 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.70 | 2021 | |
| Promius Pharma LLC | $16.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payman Sadeghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.